Different Appearances of 3 Malignancies in 68Ga-PSMA-11 Versus 18F-FDG PET/CT

Abstract

Prostate-specific membrane antigen (PSMA) overexpression has been described in various malignancies. Hereby we present a case of a 69-year-old man simultaneously diagnosed with prostate cancer, esophageal adenocarcinoma, and HCC (hepatocellular carcinoma). 18F-FDG PET/CT showed pathological uptake in the esophageal adenocarcinoma and the primary prostate tumor, whereas 68Ga-PSMA-11 PET/CT performed for staging of the histopathologically confirmed prostate cancer revealed the primary tumor and significant uptake in the HCC. This finding is remarkable because the high physiological liver uptake of 68Ga-PSMA-11 may hamper the detection of small lesions.

Intrahepatic cholangiocarcinoma detected on 18F-PSMA-1007 PET/MR imaging in a prostate cancer patient: a case report and literature review

“…The misdiagnosis of this case led us to further search and summarize positive PSMA-PET images of liver lesions in PubMed. From 2015 to 2022, a total of 17 cases underwent PSMA-PET imaging (15 of 68 Ga-PSMA and 2 of 18 F-PSMA-1007), comprising eight cases of HCC (10)(11)(12)(13)(14)(15)(16)(17), two of ICC (18,19), one of combined hepatocellular-cholangiocarcinoma (CHC) (20), one liver metastasis of cholangiocarcinoma (CCA) (21), and five benign liver lesions (22-26), as detailed in Table 1. The mean age was 74.0 ± 6.4.…”